Drug intelligence / Profile preview

poseltinib (Hanmi Pharmaceutical)

Development stage: Preclinical
Lead developer: NOBO Medicine
Modality: Small Molecules
Administration: Oral

Overview

**NOBO-203** is NOBO Medicine's Project 203 program using **poseltinib**, an orally administered small-molecule, covalent inhibitor of Bruton's tyrosine kinase and TEC kinase. The program has been listed for relapsed/refractory marginal zone B-cell lymphoma in the provided pipeline record; more recent NOBO pipeline material describes Project 203 more broadly as relapsed/refractory B-cell non-Hodgkin lymphoma. Poseltinib suppresses B-cell receptor signaling that supports malignant B-cell proliferation and survival. ([kddf.org](https://kddf.org/upload/files/1755052671_5660e7e10f877a44cc72.pdf))

Other names: poseltinib

Targets

BTK (Bruton tyrosine kinase)

Beyond the preview

Go deeper on poseltinib (Hanmi Pharmaceutical).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on poseltinib (Hanmi Pharmaceutical).

Explore the full profile